A PHASE II STUDY WITH OXALIPLATIN + 5FU + CETUXIMAB AND RADIOTHERAPY FOR TREATMENT OF NON-RESECTABLE, LOCALLY ADVANCED BUT NOT METASTATIC CANCER OF OESOPHAGUS OR THE CARDIA REGION.

Trial Profile

A PHASE II STUDY WITH OXALIPLATIN + 5FU + CETUXIMAB AND RADIOTHERAPY FOR TREATMENT OF NON-RESECTABLE, LOCALLY ADVANCED BUT NOT METASTATIC CANCER OF OESOPHAGUS OR THE CARDIA REGION.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms LERFOX-C
  • Most Recent Events

    • 06 Sep 2017 Planned End Date changed from 16 Dec 2013 to 1 Jan 2019.
    • 06 Sep 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2018.
    • 15 Nov 2014 Status changed from recruiting to discontinued
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top